Last reviewed · How we verify
Cutaneous leishmaniasis
Approved treatments
- Impavido · Knight Theraps
Impavido works by inhibiting the RAC-alpha serine/threonine-protein kinase, which is essential for the survival of Leishmania parasites.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Cutaneous leishmaniasis patent landscape — cliff calendar, originator estates, attackable patents
- Cutaneous leishmaniasis treatment landscape brief
- Cutaneous leishmaniasis treatment updates RSS
Frequently asked questions about Cutaneous leishmaniasis
What drugs treat Cutaneous leishmaniasis?
Tracked treatments include Impavido.
What is the treatment for Cutaneous leishmaniasis?
Standard treatment for Cutaneous leishmaniasis includes Impavido. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Cutaneous leishmaniasis patent cliff · Cutaneous leishmaniasis CI report
- Treatment: Impavido · Knight Theraps
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing